Santen Pharmaceutical Co., Ltd.
4536.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | ¥92,997,000 | ¥94,582,000 | ¥57,903,000 | ¥83,014,000 |
| Short-Term Investments | ¥997,000 | ¥379,000 | ¥774,000 | ¥1,293,000 |
| Receivables | ¥72,083,000 | ¥90,539,000 | ¥107,165,000 | ¥99,591,000 |
| Inventory | ¥51,590,000 | ¥43,185,000 | ¥39,352,000 | ¥37,141,000 |
| Other Curr. Assets | ¥7,630,000 | ¥7,454,000 | ¥8,132,000 | ¥8,387,000 |
| Total Curr. Assets | ¥224,300,000 | ¥236,139,000 | ¥213,326,000 | ¥229,426,000 |
| Property Plant & Equip (Net) | ¥72,954,000 | ¥71,576,000 | ¥66,173,000 | ¥56,287,000 |
| Goodwill | ¥8,242,000 | ¥8,303,000 | ¥7,385,000 | ¥13,715,000 |
| Intangibles | ¥67,225,000 | ¥75,516,000 | ¥88,924,000 | ¥116,502,000 |
| Long-Term Investments | ¥16,177,000 | ¥24,406,000 | ¥36,585,000 | ¥36,238,000 |
| Tax Assets | ¥10,017,000 | ¥10,765,000 | ¥2,810,000 | ¥3,103,000 |
| Other NC Assets | ¥10,362,000 | ¥8,994,000 | ¥5,976,000 | ¥4,706,000 |
| Total NC Assets | ¥184,977,000 | ¥199,560,000 | ¥207,853,000 | ¥230,551,000 |
| Other Assets | ¥0 | ¥0 | ¥0 | -¥1,000 |
| Total Assets | ¥409,277,000 | ¥435,699,000 | ¥421,179,000 | ¥459,976,000 |
| Liabilities | – | – | – | – |
| Payables | ¥38,989,000 | ¥24,042,000 | ¥25,282,000 | ¥24,420,000 |
| Short-Term Debt | ¥3,289,000 | ¥2,748,000 | ¥3,056,000 | ¥10,936,000 |
| Tax Payable | ¥0 | ¥5,127,000 | ¥6,745,000 | ¥4,198,000 |
| Deferred Revenue | ¥0 | ¥5,127,000 | ¥0 | ¥0 |
| Other Curr. Liab. | ¥42,320,000 | ¥47,156,000 | ¥53,001,000 | ¥52,299,000 |
| Total Curr. Liab. | ¥86,837,000 | ¥92,796,000 | ¥89,504,000 | ¥95,821,000 |
| LT Debt | ¥26,483,000 | ¥27,463,000 | ¥28,198,000 | ¥12,677,000 |
| Deferred Rev, NC | ¥744,000 | ¥738,000 | -¥28,198,000 | ¥11,161,000 |
| Deferred Tax Liab, NC | ¥2,606,000 | ¥1,377,000 | ¥1,592,000 | ¥2,526,000 |
| Other NC Liab. | ¥2,969,000 | ¥3,009,000 | ¥29,509,000 | ¥0 |
| Total NC Liab. | ¥37,260,000 | ¥37,534,000 | ¥38,378,000 | ¥27,311,000 |
| Other Liabilities | ¥0 | ¥0 | ¥0 | ¥0 |
| Cap. Leases | ¥7,472,000 | ¥4,947,000 | ¥4,953,000 | ¥6,290,000 |
| Total Liabilities | ¥124,097,000 | ¥130,330,000 | ¥127,882,000 | ¥123,132,000 |
| Equity | – | – | – | – |
| Pref Stock | ¥0 | ¥0 | ¥0 | ¥307,802,000 |
| Common Stock | ¥8,806,000 | ¥8,777,000 | ¥8,702,000 | ¥8,672,000 |
| Retained Earnings | ¥228,291,000 | ¥240,029,000 | ¥238,071,000 | ¥290,477,000 |
| AOCI | ¥40,509,000 | ¥48,413,000 | ¥37,781,000 | ¥29,686,000 |
| Other Equity | ¥0 | ¥0 | ¥0 | ¥0 |
| Total Equity | ¥286,242,000 | ¥306,055,000 | ¥293,979,000 | ¥337,488,000 |
| Supplemental Information | – | – | – | – |
| Minority Interest | -¥1,061,000 | -¥685,000 | -¥683,000 | -¥645,000 |
| Total Liab. & Tot. Equity | ¥409,277,000 | ¥435,699,000 | ¥421,861,000 | ¥460,620,000 |
| Net Debt | -¥63,225,000 | -¥64,371,000 | -¥26,649,000 | -¥59,401,000 |